# Bevacizumab

Source: https://onco.cc/drugs/bevacizumab/  
OnCo record `bevacizumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Bevacizumab is a humanised antibody that soaks up VEGF-A, the signal tumours use to grow new blood vessels. Approved in 2004, it partners chemotherapy in colorectal, ovarian, cervical, lung, kidney and liver cancer and glioblastoma, and adds to trifluridine/tipiracil in late-line bowel cancer; hypertension, protein in the urine and bleeding are its characteristic side effects.

## Summary

Humanised anti-VEGF-A IgG1. Standard with first- and second-line chemotherapy in mCRC (all RAS statuses, right-sided tumours), with trifluridine/tipiracil in refractory disease (SUNLIGHT), and in ovarian, cervical, NSCLC, RCC, HCC (with atezolizumab), and glioblastoma. Biosimilars since 2017 have cut its cost sharply. Hypertension, proteinuria, bleeding, wound-healing delay, and rare GI perforation.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-07
- Brand: Avastin (and biosimilars)
- Modality: Monoclonal antibody (anti-VEGF)
- Mechanism: Neutralises circulating VEGF-A, reducing angiogenesis and normalising tumour vasculature.
- Approvals: US 2004: First-line metastatic colorectal cancer with 5-FU chemotherapy; US 2006: NSCLC; later ovarian, cervical, RCC, glioblastoma, HCC; US 2023: Refractory mCRC with trifluridine/tipiracil (SUNLIGHT); US 2014: Platinum-resistant ovarian cancer with chemotherapy; recurrent/metastatic cervical cancer with chemotherapy; US 2018: First-line stage III-IV ovarian cancer after surgery; US 2020: First-line maintenance with olaparib in HRD-positive ovarian cancer; EU 2005: Metastatic colorectal cancer with fluoropyrimidine-based chemotherapy; England (NICE) 2026: First- and second-line metastatic colorectal cancer with fluoropyrimidine-based chemotherapy, only when targeted treatment or immunotherapy is unsuitable
- Dosing: Intravenous; 5-10 mg/kg every 2 weeks (mCRC); 15 mg/kg every 3 weeks in other tumours

## Notes

- In gynaecological oncology bevacizumab is used in first-line and recurrent ovarian cancer (GOG-0218, ICON7, OCEANS, AURELIA), as the partner for olaparib maintenance in HRD-positive disease (PAOLA-1), and in first-line cervical cancer regimens with pembrolizumab (KEYNOTE-826) or atezolizumab (BEATcc); it is given at 15 mg/kg every 3 weeks with chemotherapy and continued as maintenance. In the GOG-0218 concurrent and maintenance arm hypertension affected 42 percent (17 percent grade 3 or higher) and bowel perforation 2.6 percent.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Bevacizumab
- FDA label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125085s340lbl.pdf
- NICE TA1136: bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer: https://www.nice.org.uk/guidance/ta1136
- NICE TA212 (2010, not recommended): https://www.nice.org.uk/guidance/ta212
- EMA Avastin: https://www.ema.europa.eu/en/medicines/human/EPAR/avastin

## Connected records

- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan)](https://onco.cc/drugs/folfoxiri/), [Ziv-aflibercept](https://onco.cc/drugs/ziv-aflibercept/)
- cancers: [Adenocarcinoma of the lung](https://onco.cc/cancers/lung-adenocarcinoma/), [Adenosquamous carcinoma of the cervix](https://onco.cc/cancers/cervical-adenosquamous-carcinoma/), [Adult granulosa cell tumour of the ovary](https://onco.cc/cancers/granulosa-cell-tumour/), [Advanced and metastatic small bowel adenocarcinoma](https://onco.cc/cancers/advanced-small-bowel-adenocarcinoma/), [Advanced hepatocellular carcinoma (BCLC C)](https://onco.cc/cancers/hcc-advanced/), [Angiosarcoma](https://onco.cc/cancers/angiosarcoma/), [Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)](https://onco.cc/cancers/appendiceal-adenocarcinoma/), [Appendiceal cancer and pseudomyxoma peritonei](https://onco.cc/cancers/appendiceal/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Early hepatocellular carcinoma (BCLC 0 and A)](https://onco.cc/cancers/hcc-early/), [Early-onset colorectal cancer (under 50)](https://onco.cc/cancers/early-onset-colorectal/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)](https://onco.cc/cancers/medulloblastoma-group-3-4/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [HER2-amplified colorectal cancer](https://onco.cc/cancers/her2-amplified-colorectal/), [High-grade serous ovarian cancer](https://onco.cc/cancers/high-grade-serous-ovarian-cancer/), [HPV-associated vulvar squamous cell carcinoma](https://onco.cc/cancers/hpv-associated-vulvar-cancer/), [HPV-independent vulvar squamous cell carcinoma (p53-mutant)](https://onco.cc/cancers/hpv-independent-vulvar-cancer/), [Intermediate hepatocellular carcinoma (BCLC B)](https://onco.cc/cancers/hcc-intermediate/), [KRAS G12C-mutant colorectal cancer](https://onco.cc/cancers/kras-g12c-colorectal/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Medulloblastoma](https://onco.cc/cancers/medulloblastoma/), [Meningioma](https://onco.cc/cancers/meningioma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma](https://onco.cc/cancers/pituitary-tumours/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/), [Platinum-sensitive ovarian cancer](https://onco.cc/cancers/platinum-sensitive-ovarian-cancer/), [Rare cancers of childhood (NCI PDQ umbrella)](https://onco.cc/cancers/rare-childhood-cancers/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/), [Recurrent or metastatic cervical cancer](https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Vestibular schwannoma (acoustic neuroma)](https://onco.cc/cancers/vestibular-schwannoma/), [Vulvar cancer](https://onco.cc/cancers/vulvar/)
- technologies: [Angiogenesis and vascular normalisation models](https://onco.cc/technologies/angiogenesis-models/), [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Biosimilar manufacturing and comparability](https://onco.cc/technologies/biosimilar-manufacturing/), [Downstream purification (Protein A capture, viral clearance, polishing)](https://onco.cc/technologies/downstream-purification-chromatography/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Vitamin D and omega-3 supplementation](https://onco.cc/technologies/vitamin-d-omega3-supplementation/)
- targets: [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- companies: [Anbogen Therapeutics](https://onco.cc/companies/anbogen-therapeutics/), [Bio-Thera Solutions](https://onco.cc/companies/bio-thera-solutions/), [Biocon](https://onco.cc/companies/biocon/), [Biocon Biologics](https://onco.cc/companies/biocon-biologics/), [GI Innovation](https://onco.cc/companies/gi-innovation/), [Hetero Drugs](https://onco.cc/companies/hetero/), [Roche / Genentech](https://onco.cc/companies/roche-genentech/), [Samsung Bioepis](https://onco.cc/companies/samsung-bioepis/)
- pathways: [Colorectal cancer (KEGG map)](https://onco.cc/pathways/colorectal-cancer-signalling/), [Glioma (KEGG map)](https://onco.cc/pathways/glioma-signalling/), [Hepatocellular carcinoma (KEGG map)](https://onco.cc/pathways/hepatocellular-carcinoma-signalling/), [Intravasation & circulating tumour cells](https://onco.cc/pathways/intravasation-ctc-survival/), [Proteoglycans in cancer](https://onco.cc/pathways/proteoglycans-in-cancer/), [Renal cell carcinoma (KEGG map)](https://onco.cc/pathways/renal-cell-carcinoma-signalling/), [The angiogenic switch & tumour vessels](https://onco.cc/pathways/angiogenic-switch/), [The pre-metastatic niche](https://onco.cc/pathways/pre-metastatic-niche/), [VEGF angiogenesis](https://onco.cc/pathways/vegf-angiogenesis/)
- trials: [A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)](https://onco.cc/trials/nct06843447/), [A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc](https://onco.cc/trials/nct07216703/), [A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer](https://onco.cc/trials/nct06840002/), [A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal](https://onco.cc/trials/nct07676162/), [A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer](https://onco.cc/trials/nct07714668/), [A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.](https://onco.cc/trials/nct06982924/), [A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Meta](https://onco.cc/trials/nct04547166/), [A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT3](https://onco.cc/trials/nct07079631/), [A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advan](https://onco.cc/trials/nct07653685/), [A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]](https://onco.cc/trials/nct06783647/), [A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]](https://onco.cc/trials/nct07111546/), [A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma](https://onco.cc/trials/nct07791758/), [A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)](https://onco.cc/trials/nct07318558/), [A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma](https://onco.cc/trials/nct07297212/), [A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors](https://onco.cc/trials/nct05584670/), [A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol](https://onco.cc/trials/nct06427941/), [A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients](https://onco.cc/trials/nct06493760/), [A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.](https://onco.cc/trials/nct02734004/), [A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors](https://onco.cc/trials/nct06953323/), [A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.](https://onco.cc/trials/nct07283367/), [A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers](https://onco.cc/trials/nct07233850/), [A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer](https://onco.cc/trials/nct07474727/), [A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer](https://onco.cc/trials/nct07071714/), [A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients](https://onco.cc/trials/nct06496971/), [A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05654454/), [A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocell](https://onco.cc/trials/nct05904886/), [A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr](https://onco.cc/trials/nct06096779/), [A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors](https://onco.cc/trials/nct04931342/), [A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li](https://onco.cc/trials/nct04524871/), [A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer](https://onco.cc/trials/nct03424005/), [A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)](https://onco.cc/trials/nct03148418/), [A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC](https://onco.cc/trials/nct07244705/), [A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy](https://onco.cc/trials/nct06750094/), [A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Can](https://onco.cc/trials/nct04854668/), [A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.](https://onco.cc/trials/nct05867420/), [A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer](https://onco.cc/trials/nct07054567/), [A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct06697197/), [A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors](https://onco.cc/trials/nct06730750/), [A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors](https://onco.cc/trials/nct02671435/), [A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma](https://onco.cc/trials/nct02519348/), [A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer](https://onco.cc/trials/nct07805551/), [A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer](https://onco.cc/trials/nct07042802/), [A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)](https://onco.cc/trials/nct06796907/), [A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer](https://onco.cc/trials/nct06792695/), [A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors](https://onco.cc/trials/nct06016062/), [A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors](https://onco.cc/trials/nct06703177/), [A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors](https://onco.cc/trials/nct07448922/), [A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors](https://onco.cc/trials/nct06271837/), [A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma](https://onco.cc/trials/nct04712643/), [A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma](https://onco.cc/trials/nct05440708/), [A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients](https://onco.cc/trials/nct06497985/), [A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult](https://onco.cc/trials/nct07059845/), [A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Fo](https://onco.cc/trials/nct06890338/), [A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN1](https://onco.cc/trials/nct07024784/), [A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil,](https://onco.cc/trials/nct06820463/), [A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl](https://onco.cc/trials/nct06824467/), [A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Parti](https://onco.cc/trials/nct07221357/), [A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard ](https://onco.cc/trials/nct06948448/), [A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizu](https://onco.cc/trials/nct05824975/), [A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)](https://onco.cc/trials/nct07286266/), [A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepat](https://onco.cc/trials/nct06679985/), [A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct06512051/), [A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors](https://onco.cc/trials/nct06895928/), [A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer ](https://onco.cc/trials/nct03390686/), [A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers](https://onco.cc/trials/nct04626635/), [A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat](https://onco.cc/trials/nct06040099/), [ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct05405595/), [AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer](https://onco.cc/trials/nct06951503/), [Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC](https://onco.cc/trials/nct05192798/), [An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)](https://onco.cc/trials/nct05112965/), [Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment](https://onco.cc/trials/nct03847428/), [AURELIA](https://onco.cc/trials/aurelia/), [AVF2107g](https://onco.cc/trials/avf2107g/), [BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer](https://onco.cc/trials/nct06123884/), [BEATcc / ENGOT-Cx10 / GOG-3030](https://onco.cc/trials/beatcc/), [Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases](https://onco.cc/trials/nct07481786/), [CAIRO3](https://onco.cc/trials/cairo3/), [CAIRO5](https://onco.cc/trials/cairo5/), [CALGB 40603 (Alliance)](https://onco.cc/trials/calgb-40603/), [CALGB 90401](https://onco.cc/trials/calgb-90401/), [CALGB/SWOG 80405](https://onco.cc/trials/calgb-80405/), [CLOCC](https://onco.cc/trials/clocc/), [COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC](https://onco.cc/trials/nct04068610/), [Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer](https://onco.cc/trials/nct05757336/), [Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma](https://onco.cc/trials/nct03937830/), [COMPASSION-16 / AK104-303](https://onco.cc/trials/compassion-16/), [CRYSTAL & FIRE-3](https://onco.cc/trials/crystal-fire3/), [DUO-O / ENGOT-ov46](https://onco.cc/trials/duo-o/), [DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)](https://onco.cc/trials/nct06276283/), [Evaluating Novel Therapies in ctDNA Positive GI Cancers](https://onco.cc/trials/nct05482516/), [Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatme](https://onco.cc/trials/nct06607458/), [Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）](https://onco.cc/trials/nct07007767/), [Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer](https://onco.cc/trials/nct07235930/), [FOG-001 in Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct05919264/), [FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer](https://onco.cc/trials/nct07446322/), [Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA](https://onco.cc/trials/nct05334277/), [GeparSixto](https://onco.cc/trials/geparsixto/), [Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients](https://onco.cc/trials/nct04121455/), [GOG-0218 & ICON7 (bevacizumab)](https://onco.cc/trials/gog-0218-icon7/), [HERBY](https://onco.cc/trials/herby/), [IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer](https://onco.cc/trials/nct07722494/), [IMpower150](https://onco.cc/trials/impower150/), [INTUITT-NF2](https://onco.cc/trials/intuitt-nf2/), [Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer](https://onco.cc/trials/nct06787612/), [KEYNOTE-826](https://onco.cc/trials/keynote-826/), [KEYNOTE-B96 / ENGOT-ov65](https://onco.cc/trials/keynote-b96/), [Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV](https://onco.cc/trials/nct06782685/), [Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal C](https://onco.cc/trials/nct05445778/), [MOUNTAINEER](https://onco.cc/trials/mountaineer/), [MOUNTAINEER-03](https://onco.cc/trials/mountaineer-03/), [MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)](https://onco.cc/trials/nct07479485/), [N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma](https://onco.cc/trials/nct06061809/), [Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer](https://onco.cc/trials/nct06873763/), [Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)](https://onco.cc/trials/nct07351487/), [Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiot](https://onco.cc/trials/nct07001618/), [Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer](https://onco.cc/trials/nct04938583/), [ORIENT-32](https://onco.cc/trials/orient-32/), [Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer](https://onco.cc/trials/nct04181060/), [Pan Tumor Rollover Study](https://onco.cc/trials/nct03899155/), [PAOLA-1 / ENGOT-ov25](https://onco.cc/trials/paola-1/), [PARADIGM](https://onco.cc/trials/paradigm/), [Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer](https://onco.cc/trials/nct06976944/), [Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors](https://onco.cc/trials/nct05797168/), [Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer](https://onco.cc/trials/nct05739981/), [Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma](https://onco.cc/trials/nct06921785/), [QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC](https://onco.cc/trials/nct06786026/), [QLS5132 Combination Therapy in Advanced Solid Tumors](https://onco.cc/trials/nct07453394/), [Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers](https://onco.cc/trials/nct06906341/), [S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct05101070/), [Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases](https://onco.cc/trials/nct07623577/), [Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases](https://onco.cc/trials/nct06401824/), [Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC](https://onco.cc/trials/nct07359404/), [Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06771622/), [Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors](https://onco.cc/trials/nct04262466/), [SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer](https://onco.cc/trials/nct06465563/), [SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer](https://onco.cc/trials/nct06859775/), [Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases](https://onco.cc/trials/nct05588388/), [Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)](https://onco.cc/trials/nct05489211/), [Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer](https://onco.cc/trials/nct07527858/), [Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer](https://onco.cc/trials/nct05775159/), [Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab fo](https://onco.cc/trials/nct06106308/), [Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)](https://onco.cc/trials/nct05239741/), [Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metast](https://onco.cc/trials/nct07775287/), [Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.](https://onco.cc/trials/nct07638852/), [Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors](https://onco.cc/trials/nct06445062/), [Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC](https://onco.cc/trials/nct05733598/), [Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-](https://onco.cc/trials/nct06819007/), [Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma](https://onco.cc/trials/nct06558227/), [Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer](https://onco.cc/trials/nct07080216/), [Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unrese](https://onco.cc/trials/nct06107413/), [Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Re](https://onco.cc/trials/nct07225270/), [Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or](https://onco.cc/trials/nct07564141/), [SUNLIGHT](https://onco.cc/trials/sunlight/), [SYS6090 Combination Therapy in Advanced Lung Cancer](https://onco.cc/trials/nct07472647/), [The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospec](https://onco.cc/trials/nct06125080/), [Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Dis](https://onco.cc/trials/nct07681297/), [TRIBE](https://onco.cc/trials/tribe/), [TRIBE2](https://onco.cc/trials/tribe2/), [Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases](https://onco.cc/trials/nct06683703/)
- people: [Judah Folkman](https://onco.cc/people/judah-folkman/), [Rachel Kerr](https://onco.cc/people/rachel-kerr/), [Volker Heinemann](https://onco.cc/people/volker-heinemann/)
- key papers: [Atezolizumab plus bevacizumab in advanced malignant peritoneal mesothelioma](https://onco.cc/key-papers/paper-raghav-atezolizumab-bevacizumab-peritoneal-mesothelioma-cancer-discov-2021/), [AURELIA: bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer](https://onco.cc/key-papers/paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014/), [Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in KRAS wild-type advanced or metastatic colorectal cancer (CALGB/SWOG 80405)](https://onco.cc/key-papers/paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017/), [EMERALD-1: durvalumab with or without bevacizumab added to transarterial chemoembolisation for embolisation-eligible hepatocellular carcinoma](https://onco.cc/key-papers/paper-emerald-1-lancet-2025/), [FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3)](https://onco.cc/key-papers/paper-heinemann-fire-3-cetuximab-vs-bevacizumab-lancet-oncol-2014/), [FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of TRIBE](https://onco.cc/key-papers/paper-cremolini-tribe-folfoxiri-bevacizumab-lancet-oncol-2015/), [GOG 240: bevacizumab added to chemotherapy for advanced cervical cancer](https://onco.cc/key-papers/paper-gog-240-bevacizumab-cervical-nejm-2014/), [Hearing improvement after bevacizumab in patients with neurofibromatosis type 2](https://onco.cc/key-papers/paper-plotkin-bevacizumab-nf2-nejm-2009/), [Hurwitz 2004: bevacizumab with chemotherapy for metastatic colorectal cancer, the first anti-angiogenic drug to extend life](https://onco.cc/key-papers/paper-hurwitz-bevacizumab-crc-nejm-2004/), [IMbrave050: adjuvant atezolizumab plus bevacizumab versus active surveillance after resection or ablation of high-risk hepatocellular carcinoma](https://onco.cc/key-papers/paper-imbrave050-lancet-2023/), [Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405](https://onco.cc/key-papers/paper-lenz-cms-calgb-swog-80405-jco-2019/), [Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer](https://onco.cc/key-papers/paper-sandler-ecog-4599-bevacizumab-nsclc-nejm-2006/), [Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials](https://onco.cc/key-papers/paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017/), [Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials](https://onco.cc/key-papers/paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017/), [Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer (SUNLIGHT)](https://onco.cc/key-papers/paper-prager-sunlight-trifluridine-tipiracil-bevacizumab-nejm-2023/)
- pairings: [PARP inhibitor + bevacizumab maintenance (HRD-positive)](https://onco.cc/pairings/parp-plus-bevacizumab/)
- roadmaps: [Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation](https://onco.cc/roadmaps/colorectal-roadmap/)
- terms: [Anti-VEGF class toxicities (hypertension, proteinuria, bleeding, perforation)](https://onco.cc/terms/antiangiogenic-toxicities/), [Biologics Price Competition and Innovation Act 2010](https://onco.cc/terms/bpcia/), [Colorectal cancer drugs in England: what NICE has recommended](https://onco.cc/terms/colorectal-uk-drug-access/), [Hallmarks of cancer as a synthesis of the theories](https://onco.cc/terms/hallmarks-synthesis/), [Mechanical theory: stiffness, pressure and force as causes](https://onco.cc/terms/mechanical-theory-of-cancer/), [Microenvironment and inflammation: tumours as wounds that do not heal](https://onco.cc/terms/microenvironment-inflammation-theory/), [Radiation necrosis (brain)](https://onco.cc/terms/radiation-necrosis/), [Venous thromboembolism (VTE)](https://onco.cc/terms/vte/)
- ideas: [Make the biosimilar the default at the pharmacy for trastuzumab, bevacizumab and rituximab](https://onco.cc/ideas/idea-cost-biosimilar-default-substitution/), [Use imaging to find the window when tumour blood vessels are working properly](https://onco.cc/ideas/idea-bio2-vascular-normalisation-window/)
- biomarkers: [HRD-positive (genomic instability score)](https://onco.cc/biomarkers/hrd-positive/)

---
JSON: https://onco.cc/api/v1/entities/bevacizumab.json